Clarified Precision Medicine provides personalized therapy options for oncologists. The company’s first product ClarifiedSelect™ offers patients and providers to submit a genomic profiling test, like those done to determine cancer risk, and to receive a clear, single-page, and easy-to-understand report that ranks recommended treatment options, clinical trials, or additional testing, and a chance to connect to a precision medicine expert. This data helps supplements oncologists’ understanding and recommendation of treatment options while giving the patient a genomics-based, expert-reviewed, and clinically-actionable path forward based on their unique genetic profile.
CEO: Rajni Natesan
Headquarters: Tampa, FL
Year Founded: 2015
Year Avestria First Invested: 2023 (Fund II)
Looking for a job opportunity at Clarified? Click here.
Clarified sees seed investment as sign that market recognizes gaps
Clarified Precision Medicine announces new raise and new CEO
A serial entrepreneur and cancer survivor pitches precision medicine startup on “Closing Time”
Myriad Genetics partners with Clarified Precision Medicine
VieCure integrates the Clarified Precision Medicine process within its platform
The Carcinoid Cancer Foundation partners with Clarified Precision Medicine
Clarified Precision Medicine acquires Interpares Biomedicine
April 19, 2024: In precision oncology, the term the “last mile problem” refers to the decision support that turns a patient’s genetic profiling test results into actionable results. Clarified finishes that last mile, providing a list of recommended treatment options to help healthcare providers and patients take action. In this article, Rajni Natesen points at Clarified’s latest fundraising round as a sign that external investors are recognizing this gap and the value of Clarified’s service in terms of filling it.
April 16, 2024: Clarified Precision Medicine announced both that it had rased a $1.2M Seed round and had appointed Rajni Natesen MD MBA as its new CEO. Rajni Natesen, who has deep C-suite experience across medical devices and health-tech, will help scale and commercialize the company, taking the reins from Co-Founder and Scientific Advisor Lisa Alderson. The raise was led by Avestria Ventures and included participation by Joyance Partners.
August 19, 2023: Lisa Alderson, the Co-Founder and Scientific Advisor for Clarified Precision Medicine, was the guest on the inaugural episode of the “Closing Time” podcast. In this 40-ish minute episode, she pitched Clarified Precision Medicine to Deena Shakir - GP of Lux Capital and an investor in Clarified - and shared her own interest and passion in genomic medicine, which lead her not only to Clarified but to Genome Medical: one of Avestria’s Fund I portfolio companies.
August 23, 2022: Clarified Precision Medicine and Myraid Genetics have partnered to form the new Molecular Tumor Board. The board, which will be made up of Clarified and Myraid clinical experts, will meet virtually monthly and will provide innovative, evidence-based assessments of cancer treatment cases. The healthcare providers who use Myriad’s Precise™ Oncology Solutions will have access to this expertise as well as to Clarified’s peer-to-peer consulting services.
August 10, 2022: VieCure is integrating Clarified’s testing tools within the ViueCure cancer care platform. Starting later in the year, VieCure oncologists and clinical users will be able to access not only their molecular tests out of the VieCure platform but the ClarifiedSelect™ analysis report as well. Clarified Precision Medicine’s clinical experts will review the molecular tests results and condense them into a list of ranked treatment options and suggestions for any additional testing. Clarified’s experts will also be on-hand to discuss the results. This partnership, combining tests and an easy-to-understand analysis of those test results and the subsequent next steps, will help turn tests into actionable therapy.
September 22, 2021: The Carcinoid Cancer Foundation (CCF) and Clarified Precision Medicine have partnered to review tumor sequencing results for neuroendocrine tumor patients. Tumor sequencing finds the order of the tumor DNA; an error in the sequencing can cause cancer cells to grow and spread and neuroendocrine tumors are tumors that have developed from neuroendocrine cells. NET patients who have had a tumor sequencing test in the past two years can receive, at no cost to them, a ClarifiedSelect™ analysis, which will analyze the patient’s test results and provide a ranked list of potential treatment options, including FDA-approved treatments, off-label therapies, and clinical trials.
August 13, 2021: Clarified Precision Medicine has acquired another Tampa-based genetic company; Interpares Biomedicine. Now, Interpares’s OncoGuardian™ product is part of the Clarified Precision Medicine offerings. While Clarified Precision Medicine’s ClarifiedSelect™ product helps determine what treatments are likely to be most beneficial for the patient based on the patient’s tumor DNA, the OncoGuardian™ product determine what treatments might be harmful to the patient based on the patient’s DNA. Getting both of these pieces of information can help the patient receive a full and personalized risk and benefit profile.